- Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)
-
Yun BS, Lee KB, Lee KH, Chang HK, Kim JY, Lim MC, Choi CH, Cho H, Kim DY, Kim YH, Choi JS, Lee CH, Kim JW, Kim SW, Kim YB, Cho CH, Hong DG, Song YJ, Jeon S, Kim MK, Jeong DH, Park H, Kim SM, Park SI, Song JY, Mukhopadhyay A, Thinh DHQ, Kampan NC, Lee GJ, Kim JH, Eom KY, Roh JW
- KMID: 2564946
- J Gynecol Oncol.
- 2024 Sep;35(5):e57.
- doi: 10.3802/jgo.2024.35.e57
Background: Bulky or multiple lymph node (LN) metastases are associated with poor prognosis in cervical cancer, and the size or number of LN metastases is not yet reflected in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Step-by-step demonstration of “sciatic-nerve-preserved beyondLEER” in a Thiel-embalmed cadaver: a novel salvage surgery for recurrent gynecologic malignancies
-
Kanao H, Tamate M, Matsuura M, Nagao S, Nakazawa M, Habata S, Saito T
- KMID: 2564942
- J Gynecol Oncol.
- 2024 Sep;35(5):e112.
- doi: 10.3802/jgo.2024.35.e112
Objective: Complete resection is the curative treatment choice for recurrent gynecological malignancies. Laterally extended endopelvic resection (LEER) is an effective surgical salvage therapy for lateral recurrence. However, when a recurrent... -
- CITED
-
- Close
- SHARE
-
- Close
- First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial
-
Wu X, Liu J, An R, Yin R, Zhang Y, Zhou H, He A, Wang L, Zhang J, Liu Z, Duan W, Zhu J, Lou G, Chen G, Cheng Y, Xue F, Nick S, Wang H, Li D
- KMID: 2564957
- J Gynecol Oncol.
- 2024 Sep;35(5):e99.
- doi: 10.3802/jgo.2024.35.e99
Objective: First-line bevacizumab plus carboplatin and paclitaxel (CP) is approved for stage III/IV ovarian cancer treatment following initial surgical resection, based on global phase III GOG-0218 and ICON7 trials. This... -
- CITED
-
- Close
- SHARE
-
- Close
- Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study
-
Aoki D, Tabata T, Yanagida S, Nakamura T, Kondo E, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Kato A, Suri A, Okamoto A, Sugiyama T
- KMID: 2564943
- J Gynecol Oncol.
- 2024 Sep;35(5):e114.
- doi: 10.3802/jgo.2024.35.e114
Objective: To evaluate the long-term efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. Methods: This was the follow-up analysis of a phase 2, multicenter, open-label, single-arm... -
- CITED
-
- Close
- SHARE
-
- Close
- Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study
-
Itamochi H, Takeshima N, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Nishio S, Watari H, Yokoyama Y, Kase Y, Sumino S, Kato A, Suri A, Yasuoka T, Takehara K
- KMID: 2564944
- J Gynecol Oncol.
- 2024 Sep;35(5):e115.
- doi: 10.3802/jgo.2024.35.e115
Objective: This study evaluated the long-term safety and efficacy of niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer. Methods: This was a follow-up analysis of a phase 2, multicenter, open-label,... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness of atezolizumab plus chemotherapy for advanced/ recurrent endometrial cancer
-
Huo G, Song Y, Chen P
- KMID: 2564956
- J Gynecol Oncol.
- 2024 Sep;35(5):e83.
- doi: 10.3802/jgo.2024.35.e83
Objective: This study assessed the cost-effectiveness of atezolizumab in combination with chemotherapy for patients with advanced or recurrent endometrial cancer (EC) from the U.S. payer’s perspective. Methods: A cost-effectiveness study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience
-
Wijaya ST, Ngoi NY, Loh JW, Tan TZ, Lim D, Khan IS, Thian YL, Lai A, Ang BW, Tong P, Ng J, Low JJ, Ilancheran A, Lim SE, Lim YW, Tan DS
- KMID: 2564955
- J Gynecol Oncol.
- 2024 Sep;35(5):e69.
- doi: 10.3802/jgo.2024.35.e69
Objective: Ovarian clear cell carcinoma (OCCC) is associated with chemoresistance. Limited data exists regarding the efficacy of targeted therapies such as immune checkpoint inhibitors (ICI) and bevacizumab, and the role... -
- CITED
-
- Close
- SHARE
-
- Close
- Patient and clinician priorities for information on treatment outcomes for advanced ovarian cancer: a Delphi exercise
-
Baxter K, Agnew H, Morgan J, Holland C, Flynn D, Edmondson R
- KMID: 2564952
- J Gynecol Oncol.
- 2024 Sep;35(5):e63.
- doi: 10.3802/jgo.2024.35.e63
Objective: Patients with advanced ovarian cancer face a range of treatment options, and there is unwarranted variation in treatment decision-making between UK providers. Decision support tools that produce data on... -
- CITED
-
- Close
- SHARE
-
- Close
- TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway
-
Xue F, Liu L, Tao X, Zhu W
- KMID: 2564953
- J Gynecol Oncol.
- 2024 Sep;35(5):e64.
- doi: 10.3802/jgo.2024.35.e64
Objective: Src homology phosphotyrosin phosphatase 2 (SHP2) has been implicated in the progression of several cancer types. However, its function in endometrial cancer (EC) remains unclear. Here, we report that... -
- CITED
-
- Close
- SHARE
-
- Close
- CDK1 promotes the phosphorylation of KIFC1 to regulate the tumorgenicity of endometrial carcinoma
-
Lin X, He Y, Liu Y, Zhou H, Xu X, Xu J, Zhou K
- KMID: 2564954
- J Gynecol Oncol.
- 2024 Sep;35(5):e68.
- doi: 10.3802/jgo.2024.35.e68
Objective: This study aims to clarify the mechanical action of cyclin-dependent protein kinase 1 (CDK1) in the development of endometrial carcinoma (EMCA), which may be associated with the phosphorylation of... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan
-
Machida H, Matsuo K, Higashi T, Aoki D, Enomoto T, Okamoto A, Katabuchi H, Nagase S, Mandai M, Yaegashi N, Yamagami W, Mikami M
- KMID: 2564950
- J Gynecol Oncol.
- 2024 Sep;35(5):e61.
- doi: 10.3802/jgo.2024.35.e61
Objective: Hospital treatment volume affects survival in patients with endometrial cancer; notably, initial treatment at high-volume centers improves survival outcomes. Our study assessed the effect of hospital treatment volume on cost-effectiveness... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of outcomes of laparotomic and minimally invasive radical hysterectomy in women with early-stage cervical cancer
-
Chang SH, Huang KG, Yang LY, Pan YB, Lai CH, Chou HH
- KMID: 2564949
- J Gynecol Oncol.
- 2024 Sep;35(5):e60.
- doi: 10.3802/jgo.2024.35.e60
Objective: This study compared the outcomes of laparotomic radical hysterectomy (LRH) and minimally invasive radical hysterectomy (MISRH) in patients with early-stage cervical cancer. Methods: The clinical data of patients with early-stage... -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial
-
Alnemr AA, Harb OA, Atia H
- KMID: 2564951
- J Gynecol Oncol.
- 2024 Sep;35(5):e62.
- doi: 10.3802/jgo.2024.35.e62
Objective: To compare the efficacy of the levonorgestrel intrauterine system (LNG-IUS) versus megestrol acetate (MA) in inducing complete regression among women with atypical endometrial hyperplasia (AEH) who declined hysterectomy. Methods: In... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
-
Huo G, Liu W, Chen P
- KMID: 2564947
- J Gynecol Oncol.
- 2024 Sep;35(5):e58.
- doi: 10.3802/jgo.2024.35.e58
Objective: To evaluate the cost-effectiveness of tisotumab vedotin to treat recurrent or metastatic cervical cancer in second- or third-line from the U.S. payer perspective. Methods: A Markov model with three-state was... -
- CITED
-
- Close
- SHARE
-
- Close
- The new 2023 FIGO staging system for endometrial cancer: what is different from the previous 2009 FIGO staging system?
-
Han KH, Park N, Lee M, Lee C, Kim H
- KMID: 2564948
- J Gynecol Oncol.
- 2024 Sep;35(5):e59.
- doi: 10.3802/jgo.2024.35.e59
Objective: The International Federation of Gynecology and Obstetrics committee modified the endometrial cancer (EC) staging system based on the histopathological feature and molecular profile. The aim is to evaluate the... -
- CITED
-
- Close
- SHARE
-
- Close
- HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010–2021): a retrospective study
-
Na YJ, Jeong O, Seong J, Lee J, Lee SY, Hur S, Ryou S
- KMID: 2564945
- J Gynecol Oncol.
- 2024 Sep;35(5):e56.
- doi: 10.3802/jgo.2024.35.e56
Objective: To evaluate human papillomavirus (HPV) vaccine effectiveness in a cohort of Korean women infected with HPV. Methods: From 2010 to 2021, Korean women aged 20–60 years who diagnosed HPV-positive atypical... -
- CITED
-
- Close
- SHARE
-
- Close
